B
ucindolol, investigated in the BEST (β-Blocker Evaluation of Survival Trial) for patients with advanced (New York Heart Association III/IV) chronic heart failure (HF) with reduced ejection fraction (HFrEF), has been associated with improved survival compared with placebo in a subgroup of subjects with ADRB1 (β-1 adrenergic receptor) genotype Arg389Arg. [1] [2] [3] This finding sparked interest to explore a possible clinical application of β-blocker (BB) pharmacogenetics. 4 However, most subsequent studies with other BBs have not evaluated differences in clinical outcomes by ADRB1 polymorphisms. [5] [6] [7] [8] [9] The singular exception is the HF-ACTION trial (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), in which the Arg389Arg but not 389Gly genotype was associated with mortality reduction for higher dose BBs. 10, 11 The first objective of the current study was to examine dose-related aspects of BB interactions with the ADRB1 Arg389Gly polymorphism, emphasizing uniform methodology applied to the BEST/bucindolol and HF-ACTION/ other BB databases. Because bucindolol, unlike other BB, has sympatholytic properties known to be modulated by the α2C adrenergic receptor (ADRA2C) Ins322-325Del polymorphism, 12 we also investigated the impact of this polymorphism in both trials. A schematic representation of ADRB1 Arg389Gly and ADRAC Ins322-325Del polymorphisms on the human cardiac sympathetic neuroeffector system is given in Figure I in the Data Supplement.
METHODS
A subset of the data generated for this study will be available from the corresponding author on reasonable request. Protocols for HF-ACTION and BEST were reviewed and approved by the appropriate institutional review board or ethics committee for each participating center and by the coordinating center's institutional review board. All patients provided written voluntary informed consent.
The Methods section of this study, including scheme for BB dose standardization (Table I in 
RESULTS
The analyzed DNA substudy populations included 1035 of the 2708 BEST entire cohort and 957 of 2331 total HF-ACTION subjects, representing participants in each trial that had successful ADRB1 Arg389Gly genotyping (100% in BEST and 98.1% in HF-ACTION) and a full complement of recorded variables used in covariate analysis. In BEST, 570 (55.1%) DNA substudy participants received no/lowdose bucindolol, including 525 on placebo (92.1%), and had baseline characteristics similar to those taking highdose bucindolol (Table 1) . In HF-ACTION, which was not placebo controlled, the no/low-dose BB group (n=471; 49.2%) included 416 subjects (88.3%) on low-dose BB; these participants were overall older with more ischemic HF and more likely to be nonblack leading to fewer with ADRA2C 322-325Del carrier genotype. These patterns were observed within ADRB1 and ADRA2C variants, with the additional finding of less aldosterone antagonist use among HF-ACTION subjects with homozygosity for either major allele (BEST, Table II in the Data Supplement; HF-ACTION, Table III in the Data Supplement) .
Because of the degree of HF and relatively long followup, both DNA substudies had a large number of all-cause mortality (ACM; HF-ACTION, 125; BEST, 186) or cardiovascular mortality/heart failure hospitalization (CVM/HFH) (HF-ACTION, 270; BEST, 405) events (Tables 2 and 3 ). Figure 1 ). Low-dose (>0-25 mg) Arg389Arg patients had a higher event rate than placebo patients (P=0.006; Table IV in the Data Supplement).
ADRB1 Arg389Gly Polymorphism
CVM/HFH event rates have not been previously reported for the BEST cohort, and HRs are given in Table V Figure 2 ). The genotype-dose relationship was also examined by dose intervals. The Arg389Arg patients on no BB had a higher ACM event rate than the cognate 389Gly carrier group (34.8% versus 12.5%; P=0.048), although the comparison was based on only 12 events (Table VI in the Data Supplement).
For CVM/HFH, within ADRB1 genotypes, the effects of high-versus no/low-dose were similar to those for ACM (Table 3 ; Figure III in the Data Supplement). The Arg389Arg versus 389Gly carrier comparison within high-and no/low-dose groups was also similar to ACM data, except in the no/low-dose group an increased CVM/HFH rate in Arg389Arg versus 389Gly carrier genotypes was not observed (HR, 1.28 with 95% CI of 0.91-1.80; P=0.16; Figure III in the Data Supplement).
ADRA2C Ins322-325Del Polymorphism

BEST/Bucindolol
For ACM, there was no effect of high-versus no/ low-dose bucindolol when subjects were grouped by ADRA2C genotype (HR, 0.62 for Del carriers; HR, 0.63 for Ins/Ins; HR, 0.59 for entire DNA substudy cohort) or CVM/HFH (HR, 0.65 for Del carriers; HR, 0.59 for Ins/Ins; HR, 0.87 for entire DNA substudy cohort; Table 2 ).
HF-ACTION/Other BB
Similar to BEST/bucindolol, high-dose BB did not affect ACM in subjects when grouped by ADRA2C genotype (HR, 0.72 for Del carriers; HR, 0.59 for Ins322-325Ins; HR, 0.73 for entire DNA substudy cohort) or CVM/HFH (HR, 0.75 for Del carriers; HR, 0.89 for Ins322-325Ins; HR, 0.87 for entire DNA substudy cohort; Table 3 ).
Combinatorial Genotypes
BEST/Bucindolol
When assessed by ADRA2C genotype combinations, ADRB1 Arg389Arg but not 389Gly carrier combinations showed major dose relatedness. A complete loss of efficacy for high-dose bucindolol was observed for the ADRA2C Del carrier+ADRB1 Gly carrier genotype (HR, 1.06 [0.43-2.59]; P=0.90; Table 2 ).
HF-ACTION/Other BB
For ACM and CVM/HFH, there was no evidence that ADRA2C Ins322-325Del genotype influenced any of the ADRB1 Arg389 genotype/dose interactions (Table 3) .
DISCUSSION
For treatment with bucindolol and other BBs, ADRB1 genotypes and BB dose significantly interacted with ACM risk. In both trials, high-dose BB was much more effective than no/low dose in the ADRB1 Arg389Arg In addition to ADRB1 Arg389Gly genotypes, we investigated BB dose effects related to the ADRA2C Ins322-325Del polymorphism, where the 322-325Del allele is associated with dysregulation of norepinephrine release.
12,13 For bucindolol versus placebo, ADRA2C
Ins322-325Ins genotype irrespective of dose has been shown to identify enhanced versus no clinical response 12 and differentiate nonresponse from intermediate response among ADRB1 Arg389Gly carrier patients. 2 In the current analysis of high-versus no/low-dose bucindolol, the ADRA2C Ins322-325Del polymorphism did not differentiate response to bucindolol, either alone or in combination with ADRB1 389 genotype. In HF-ACTION, ADRA2C 322 to 325 genotype did not affect clinical outcome response to other BBs, in agreement with a previous study. 14 Although a prior epidemiological study demonstrated a synergistic relationship between ADRB1 Arg389Arg and ADRA2C Del322-325Del for development of HFrEF, 15 our findings do not support the use of ADRA2C genotype to predict optimal BB dose for clinical outcomes.
Effects of high-dose bucindolol have been previously described for HF end points and arrhythmias and are attributed to selective inverse agonism or norepinephrine-lowering properties impacting high norepinephrine affinity ADRB1 Arg389 receptors. 2, 3, 16, 17 However, the finding of an increase in ACM in ADRB1 Arg389Arg versus 389Gly carrier subjects receiving low-dose other BBs has not been reported and is of unclear origin. There was also a hint of a similar effect in ADRB1 Arg389Arg BEST patients receiving >0 to 25 mg low-dose bucindolol, but the limited number of ACM events (n=10) precluded interpretation. The mechanistic possibilities for a differential increase in ACM in ADRB1 Arg389Arg patients receiving low-dose BBs include (1) selection of patients in the no/low-dose group who could not tol- ADRB1 (β-1 adrenergic receptor erate high-dose BBs, where because of differences in HF severity, the ADRB1 Arg389Arg genotype was associated with worse outcomes compared with 389Gly carriers, and (2) an adverse pharmacological effect of low-dose other BBs in ADRB1 Arg389Arg patients. Regarding the former possibility, covariate adjustment was performed for most factors that might influence outcome, but Cox modeling may not have adequately corrected for increased risk in the low/no-dose group.
Alternatively, upregulation of desensitized ADRB1 signal transduction is a possibility for an adverse pharmacological effect of no/low-dose other BB, 18 when combined with inadequate receptor occupancy for sufficient β-blockade. Regardless of the mechanism, for ACM, we have demonstrated that unlike for bucindolol in BEST, the previously reported 10 pharmacogenetically greater therapeutic effect of other BBs with high-dose BB in patients with HFrEF with an ADRB1 Arg389Arg genotype is not because of favorable effects versus 389Gly carriers but rather because of worse outcomes in the Arg389Arg no/low-dose group.
Clinical Implications
The ADRB1 Arg389Arg versus its counterpart Gly carrier genotype is the most useful to predict enhanced efficacy of bucindolol taken at high doses. In contrast, HFrEF subjects with the Arg389Arg genotype taking usual care, other BBs at low dose have significantly worse survival than their 389Gly counterparts. These observations highlight a potential role for pharmacogenomics in clinical practice to predict optimal BB dose.
Limitations
The data sources were from clinical trial substudies, but the number of ACM or CVM/HFH events was substantial and in the range of what is reported in entire cohorts of some phase 3 trials. 19, 20 The 2 analyzed DNA substudies, both prospectively designed, represent the largest 2 cohorts of patients with HFrEF with genotyping for ADRB1 polymorphisms, documentation of BB use, and assessment of standard clinical HFrEF end points. Although the methodologic approach was the same between the 2 databases because BEST was a placebo-controlled trial and HF-ACTION was not, there were more patients on no BB in BEST versus HF-ACTION. However, effects of lowdose bucindolol in ADRB1 Arg389Arg versus Arg389Gly genotypes were similar to that for placebo (enhanced efficacy in the Arg389Arg genotype was observed only for individual dose subgroups >25 mg). Although reasons for not being on a BB differ by trial, we examined genotype differences within dosing interval in each trial separately. Finally, the combinatorial genotype analysis was limited by small sample sizes for several subgroups.
Conclusions
BB dose effects on ACM or CVM/HFH risk may be observed for patients with HFrEF with an ADRB1 Arg389Arg genotype. The observed decreased risk compared with the alternative 389Gly carrier genotype may be because of a true reduction in event rates at high/target doses (bucindolol in BEST) or an increase in event rates with lower doses (other BB in HF-ACTION). These data support guideline recommendations that in HFrEF, BBs should be used at the higher target doses used in all positive phase 3 trials. The potential role for ADRB1 genotype to assess risk with low-dose BB needs prospective study. ACM indicates all-cause mortality; ADRA2C, α2C adrenergic receptor; ADRB1, β-1 adrenergic receptor; BEST, β-Blocker Evaluation of Survival Trial; HF, heart failure; HR, hazard ratio; and NYHA, New York Heart Association.
ARTICLE INFORMATION
*BEST placebo patients and bucindolol patients with exposure ≤25 mg/d are assigned to no/low-dose group. Patients with exposure >25 mg/d are assigned to high-dose group. †Generated by Cox model with the following covariates: serum creatinine, sex, ejection fraction, NYHA class, ischemic HF pathogenesis, wide QRS, history of atrial fibrillation/atrial flutter, aldosterone antagonist, and angiotensin-converting enzyme inhibitor. Parameterized to quantify benefit of high dose relative to low dose.
